Glenmark Pharmaceuticals Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Glenmark Pharmaceuticals has allotted 12,653 equity shares under ESOP. Consequently, the paid up equity share capital has increased 28,22,00,809 equity shares of Re. 1 each aggregating to Rs. 28,22,00,809/-.

Powered by Capital Market - Live News

The company will launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (mixed salts of a single entity Amphetamine product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg.

Glenmark?s product is bioequivalent and therapeutically equivalent to the reference listed drug, Adderall Tablets (5 mg to 30 mg), marketed by Teva Women?s Health, Inc. Distribution is scheduled to begin in May 2025.

According to IQVIA, sales data for the 12-month period ending February 2025, the Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market achieved annual sales of approximately $421.7 million.

Commenting on the launch, Marc Kikuchi, president & business head, North America said, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is a highly prescribed medication in the United States. Glenmark is very pleased to be able to help alleviate the shortage this country has been facing with this upcoming launch.?

Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of cardiometabolic, respiratory, dermatology and oncology.

The company reported a consolidated net profit of Rs 347.96 crore in Q3 FY25 as compared with net loss of Rs 351.37 crore in Q3 FY24. Net sales increased 34.2% YoY to Rs 3,301.90 crore in Q3 FY25.

The counter declined 1.34% to settle at Rs 1,356.95 on Wednesday, 17 April 2025.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg.

Glenmark's Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is bioequivalent and therapeutically equivalent to the reference listed drug, Adderall?2 Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, of Teva Women's Health, Inc. and the company will begin distribution in May 2025.

According to IQVIA sales data for the 12-month period ending February 2025, the Adderall? Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market achieved annual sales of approximately $421.7 million.

Powered by Capital Market - Live News

The company will launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (mixed salts of a single entity Amphetamine product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg.

Glenmark?s product is bioequivalent and therapeutically equivalent to the reference listed drug, Adderall Tablets (5 mg to 30 mg), marketed by Teva Women?s Health, Inc. Distribution is scheduled to begin in May 2025.

According to IQVIA, sales data for the 12-month period ending February 2025, the Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market achieved annual sales of approximately $421.7 million.

Commenting on the launch, Marc Kikuchi, president & business head, North America said, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is a highly prescribed medication in the United States. Glenmark is very pleased to be able to help alleviate the shortage this country has been facing with this upcoming launch.?

Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of cardiometabolic, respiratory, dermatology and oncology.

The company reported a consolidated net profit of Rs 347.96 crore in Q3 FY25 as compared with net loss of Rs 351.37 crore in Q3 FY24. Net sales increased 34.2% YoY to Rs 3,301.90 crore in Q3 FY25.

The counter declined 1.34% to settle at Rs 1,356.95 on Wednesday, 17 April 2025.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg.

Glenmark's Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is bioequivalent and therapeutically equivalent to the reference listed drug, Adderall?2 Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, of Teva Women's Health, Inc. and the company will begin distribution in May 2025.

According to IQVIA sales data for the 12-month period ending February 2025, the Adderall? Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market achieved annual sales of approximately $421.7 million.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1371.95, down 0.32% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 2.16% on the day, quoting at 22882.3. The Sensex is at 75328, up 2.01%.Glenmark Pharmaceuticals Ltd has lost around 3.54% in last one month.Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has increased around 0.27% in last one month and is currently quoting at 19976.3, up 2.51% on the day. The volume in the stock stood at 4.59 lakh shares today, compared to the daily average of 6.56 lakh shares in last one month.

The benchmark April futures contract for the stock is quoting at Rs 1376.9, up 0.02% on the day. Glenmark Pharmaceuticals Ltd jumped 30.44% in last one year as compared to a 1.61% rally in NIFTY and a 9% spurt in the Nifty Pharma index.

The PE of the stock is 16.86 based on TTM earnings ending December 24.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals has allotted 12,653 equity shares under ESOP. Consequently, the paid up equity share capital has increased 28,22,00,809 equity shares of Re. 1 each aggregating to Rs. 28,22,00,809/-.

Powered by Capital Market - Live News

The company will launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (mixed salts of a single entity Amphetamine product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg.

Glenmark?s product is bioequivalent and therapeutically equivalent to the reference listed drug, Adderall Tablets (5 mg to 30 mg), marketed by Teva Women?s Health, Inc. Distribution is scheduled to begin in May 2025.

According to IQVIA, sales data for the 12-month period ending February 2025, the Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market achieved annual sales of approximately $421.7 million.

Commenting on the launch, Marc Kikuchi, president & business head, North America said, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is a highly prescribed medication in the United States. Glenmark is very pleased to be able to help alleviate the shortage this country has been facing with this upcoming launch.?

Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of cardiometabolic, respiratory, dermatology and oncology.

The company reported a consolidated net profit of Rs 347.96 crore in Q3 FY25 as compared with net loss of Rs 351.37 crore in Q3 FY24. Net sales increased 34.2% YoY to Rs 3,301.90 crore in Q3 FY25.

The counter declined 1.34% to settle at Rs 1,356.95 on Wednesday, 17 April 2025.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg.

Glenmark's Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is bioequivalent and therapeutically equivalent to the reference listed drug, Adderall?2 Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, of Teva Women's Health, Inc. and the company will begin distribution in May 2025.

According to IQVIA sales data for the 12-month period ending February 2025, the Adderall? Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market achieved annual sales of approximately $421.7 million.

Powered by Capital Market - Live News

The company will launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (mixed salts of a single entity Amphetamine product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg.

Glenmark?s product is bioequivalent and therapeutically equivalent to the reference listed drug, Adderall Tablets (5 mg to 30 mg), marketed by Teva Women?s Health, Inc. Distribution is scheduled to begin in May 2025.

According to IQVIA, sales data for the 12-month period ending February 2025, the Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market achieved annual sales of approximately $421.7 million.

Commenting on the launch, Marc Kikuchi, president & business head, North America said, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is a highly prescribed medication in the United States. Glenmark is very pleased to be able to help alleviate the shortage this country has been facing with this upcoming launch.?

Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of cardiometabolic, respiratory, dermatology and oncology.

The company reported a consolidated net profit of Rs 347.96 crore in Q3 FY25 as compared with net loss of Rs 351.37 crore in Q3 FY24. Net sales increased 34.2% YoY to Rs 3,301.90 crore in Q3 FY25.

The counter declined 1.34% to settle at Rs 1,356.95 on Wednesday, 17 April 2025.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg.

Glenmark's Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is bioequivalent and therapeutically equivalent to the reference listed drug, Adderall?2 Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, of Teva Women's Health, Inc. and the company will begin distribution in May 2025.

According to IQVIA sales data for the 12-month period ending February 2025, the Adderall? Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market achieved annual sales of approximately $421.7 million.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1371.95, down 0.32% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 2.16% on the day, quoting at 22882.3. The Sensex is at 75328, up 2.01%.Glenmark Pharmaceuticals Ltd has lost around 3.54% in last one month.Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has increased around 0.27% in last one month and is currently quoting at 19976.3, up 2.51% on the day. The volume in the stock stood at 4.59 lakh shares today, compared to the daily average of 6.56 lakh shares in last one month.

The benchmark April futures contract for the stock is quoting at Rs 1376.9, up 0.02% on the day. Glenmark Pharmaceuticals Ltd jumped 30.44% in last one year as compared to a 1.61% rally in NIFTY and a 9% spurt in the Nifty Pharma index.

The PE of the stock is 16.86 based on TTM earnings ending December 24.

Powered by Capital Market - Live News